Purpose of Review The purpose of this review is to summarize the prevalence and clinical implications of the isolated anti-HBc serologic profile in HIV-infected individuals. We highlight the rare but important issue of HBV reactivation in the setting of HCV therapy and describe an approach to management. Recent Findings The isolated anti-HBc pattern, a profile that most often indicates past exposure to HBV with waning anti-HBs immunity, is found commonly in HIV-infected individuals, particularly those with HCV. Some large cohort studies demonstrate an association with advanced liver disease, while others do not. Conversely, meta-analyses have found an association between occult HBV infection (a component of the isolated anti-HBc pattern) and advanced liver disease and hepatocellular carcinoma in HIV-uninfected individuals. In HIV-uninfected individuals with anti-HBc positivity, HBV reactivation has been reported in patients receiving HCV therapy. This phenomenon is likely the result of disinhibition of HBV with HCV eradication. Summary In HIV-infected patients, the long-term liver outcomes associated with the isolated anti-HBc pattern remain to be fully elucidated, supporting the need for large cohort studies with longitudinal follow-up. HBV reactivation during HCV DAA therapy has been well-described in HIV-uninfected cohorts and can inform algorithms for the screening and management of the isolated anti-HBc pattern in this population.
Introduction
The isolated hepatitis B core antibody serologic profile, defined as a positive anti-HBc with negative HBsAg and anti-HBs, occurs in up to 37% of HIV co-infected with hepatitis C virus (HCV) [1] . Isolated hepatitis B core antibodies (anti-HBc) in the absence of HBsAg and anti-HBs pose challenges in interpretation and management for providers. Understanding the management of the isolated anti-HBc profile in the context of HBV prevention and HCV therapy is important given the ramifications for HBV susceptibility and HBV reactivation. The purpose of this review is to examine the prevalence, clinical implications, and management of the isolated anti-HBc profile, with special attention to direct-acting antiviral therapy for patients with chronic HCV infection.
Hepatitis B Virus Life Cycle
Hepatitis B virus establishes itself in chronic infection by way of dynamic processes involving viral and host immunity defenses (see Fig. 1 ). Attachment entry of the HBV virus requires interaction between HBsAg and hepatocyte surface proteins. HBV-relaxed circular DNA (rcDNA) is converted to covalently closed circular DNA (cccDNA), which serves as a transcriptional template for subsequent viral mRNA production and pregenomic RNA (pgRNA). This matures into nucleocapsid with viral polymerase, for viral propagation in the forms of virions outside the hepatocyte, or return to the nucleus as cccDNA [2] . The persistence of cccDNA despite effective inhibition of HBV viral polymerase through nucleos(t)ide analogues is the key reason why cure of HBV remains elusive [3] , as it provides a transcriptional reservoir for continued replication of virus [4] . The presence of cccDNA also leads to production of the core antigen (CrAg) to which antibody is formed in the form of anti-HBc. This explains why anti-HBc is present in acute, chronic, and resolved infection.
Hepatitis B Serologic Markers and Definition of the Isolated Anti-HBc Serologic Profile
As hepatitis B infection progresses or resolves, clinical states of infection are reflected in HBV serologies. The presence of hepatitis B surface antigen (HBsAg) marks active acute or chronic HBV infection. Suboptimal immune responses due to host factors such as age at time of exposure, or advanced immunosuppression, increase the risk for chronic HBV and subsequent complications. Due to mechanisms of immune control, and the presence of covalently closed circular DNA (cccDNA) that persists lifelong after HBV exposure, HBV reactivation is always possible even following immunologic recovery and clearance of HBsAg. During chronic infection, markers for HBeAg and anti-HBe may be helpful in delineating phases of chronic HBV infection. Hepatitis B core antibody (anti-HBc) may be seen in acute or chronic infection, and also may persist for life after immunity is developed (resolved infection). As infection resolves, hepatitis B surface antibody (anti-HBs) develops. Anti-HBs, in the absence of HBsAg or anti-HBc, denotes immunity from hepatitis B vaccination. The isolated anti-HBc profile is defined as the presence of anti-HBc in the absence of HBsAg and anti-HBs. Interpretations of hepatitis B serologies are listed in (Table 1) .
Interpretation of the Isolated Anti-HBc Pattern (Table 1) Several potential clinical interpretations of isolated anti-HBc are considered in the evaluation of HBV serologies including (1) resolved HBV infection with very low levels of anti-HBs undetectable with current assays, due to waning immunity; (2) occult HBV, the presence of HBV viremia, often a result of mutant HBsAg, which is not detected on standard serological testing for HBV; (3) the window period of acute HBV infection where immune complexes precipitate from HBsAg and HBsAb, thereby creating an apparent isolated anti-HBc pattern which serologically evolves with time; and (4) false positive tests, which may be found in low prevalence populations or artificial circumstances related to assay quality and technical preparation.
The most common reason for the isolated anti-HBc pattern is likely waning immunity. This is best demonstrated by an HBV serologic study conducted in the MACS cohort, a large cohort of HIV-infected and HIV-uninfected participants. In this cohort, which assessed change in HBV serologies over time, the antiHBc pattern was consistently positive in~80% of participants. The most common transitions of the isolated anti-HBc profile were to gain or lose anti-HBs, suggesting that the low or intermittently undetectable anti-HBs represented resolved HBV infection, as opposed to occult HBV viremia [5] . One limitation to this study was that HBV viremia was not assessed, but other studies (see below) have reported low rates of occult HBV viremia in those with the isolated anti-HBc profile [6] .
Mechanisms of the Isolated Anti-HBc Pattern Hepatitis B virus persists as cccDNA following exposure. Persistent HBV infection with low or undetectable levels of HBV viremia in the setting of an isolated anti-HBc potentially involves methylation of HBV cccDNA within the hepatocyte [7] , thereby Fig. 1 downregulating DNA and subsequent mRNA expression, with subsequent quiescence of HBsAg production [8] . Other epigenetic factors such as downregulation of acetylation may also play important roles towards transcriptional suppression of cccDNA in hepatocytes to explain serological patterns noted in patients with the isolated anti-HBc profile.
Prevalence and Predictors of the Anti-HBc Serologic Profile and Occult HBV Infection in HIV Infection
Wide variation exists on the prevalence of isolated anti-HBc findings. In HIV+ cohorts, 7 to 40% of patients have been reported to have the isolated anti-HBc [1, 5, 6, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] , owing to similar routes of transmission for HIV and HBV. Predictors of the isolated anti-HBc pattern include HIV infection [5, 24, 25] , HCV infection [5] , and specifically HCV viremia [25] , older age [24] , IDU, multiple sexual partners, and elevated HIV RNA levels [25] . The isolated anti-HBc pattern is particularly common in HIV/HCV co-infection, likely due to shared routes of transmission and viral interplay (see below). Estimates of prevalence of isolated anti-HBc may be limited due to differences in geography, as well as sensitivities of different immunoassays used in each study. This is in contrast to HIV-negative cohorts, where the prevalence of the isolated anti-HBc ranges from 5.3 to 31.6% [5, 14] .
The definition of occult HBV varies across studies; some define occult HBV infection as HBV DNA positivity with HBsAg negativity, regardless of anti-HBc status, while other studies define occult HBV as HBV viremia only in the setting of the isolated anti-HBc profile. Several studies have assessed the prevalence of occult HBV infection among patients with HIV and isolated anti-HBc, which has been reported to range from 0.6 [11] to 2.5% noted in the BHOI study [9] , to as high as > 89.5% in a Swiss cohort study [23] . In the Women's Interagency Cohort Study (WICS), 2% of women with HIV and a pattern of isolated HBcAb were found to have detectable HBV DNA [14] . Occult HBV viremia was associated with severe immunosuppression with CD4 < 200 cells/mm 3 in the WIHS cohort.
Association With Advanced Liver Disease and Its Complications
The association with the isolated anti-HBc pattern and advanced liver disease is difficult to ascertain, in part, because studies have assessed the association of advanced liver disease with both the isolated anti-HBc pattern and occult HBV infection, which is a component of the isolated anti-HBc pattern but not its sole etiology. When assessing the isolated anti-HBc pattern overall, varying liver progression outcomes have been observed in HIV-infected cohorts (Table 2) . One study of 344 HIV+ women suggested that the isolated anti-HBc pattern was not associated with accelerated liver progression over a median 9.5 years [25] . In contrast, a large American cross-sectional analysis in the Veterans Aging Cohort Study (VACS) found that isolated anti-HBc in patients with HIV/HCV co-infection was associated with more advanced hepatic fibrosis, as defined by APRI and FIB-4 scores [1] . These differences may lie in differences in study design (cross-sectional vs longitudinal), and study populations as women are less likely to have liver disease progression, compared to men.
When specifically evaluating occult HBV infection in HIV infection, again varying associations are reported. In one cross-sectional analysis of HIV-infected women, there was no association with elevated transaminases [14] . In the setting of antiretroviral therapy initiation, two studies have demonstrated no impact on subsequent ALT elevation with ART 
Resolving acute infection
HBsAg hepatitis B surface antigen, Anti-HBc IgM antibody to hepatitis B core antigen, Anti-HBs antibody to HBsAg Table 2 Prevalence of, and association with, liver disease outcomes in patients with the isolated anti-HBc serologic profile and/or occult HBV infection in HIV-infected cohorts initiation in those with occult HBV infection [22, 26] , while another demonstrated elevated aminotransferases in those with HIV and OBI during ART initiation or change [21] . With regard to HBV perinatal transmission, there was no HBV perinatal transmission in a cohort of HIV-infected Thai women with occult HBV infection [10] .
In non-HIV-infected populations, however, the association between occult HBV infection and adverse outcomes seems clearer. Two large meta-analyses have found an association with occult HBV infection and chronic liver disease and hepatocellular carcinoma [27, 28] with varying prevalence and impact depending on geography and endemicity of HBV [29] . In one study, patients with chronic hepatitis C with concomitant occult hepatitis B infection had a higher risk of death related to liver disease as compared to patients without evidence of occult HBV infection over a median of 11 years of follow-up [30] . It is notable that another small study demonstrated no association between isolated anti-HBc and increased hepatocellular carcinoma risk [31] [32] [33] [34] [35] [36] although there has thus far been no association between occult HBV infection and HCV therapy response rates in the all oral direct-acting antiviral (DAA) era.
Clinical Implications and the Management of the Isolated Anti-HBc Serologic Profile in HIV Infection

Susceptibility to HBV Infection
In HIV infection, the presence of the isolated anti-HBc pattern does not necessarily indicate immunity to HBV infection. Indeed, varying anamnestic responses to a single dose of HBV vaccine have been reported, ranging from as low as 7 [37] to 32% [38] , with higher levels of response to multiple doses of HBV vaccine administered. A prospective study conducted by Piroth and colleagues demonstrated that in 54 HIVinfected patients with the isolated anti-HBc profile, a single dose of 20 μg HBV vaccine resulted in a 46% response rate, defined as anti-HBs > 10 mIU/ml; in those who did not respond to a single dose, a three-dose series of double-dose 40 μg HBV vaccine resulted in 89% of remaining patients developing anti-HBs titers of > 10 mIU/mL at 28 weeks following vaccination [39] . Based on the results of this study, the current DHHS guidelines recommend that HIV-infected patients with the isolated anti-HBc profile receive one standard dose of HBV vaccine followed by anti-HBs assessment 1-2 months post-dose. If anti-HBs is < 100 IU/mL, then the individual should receive the full series of either single-or double-dose HBV vaccine, with subsequent anti-HBs testing 1-2 months after completion of the vaccine series [40] .
HBV Reactivation During DAA-Therapy in HCV-Infected Patients
With the advent of direct-acting antiviral (DAA) therapy for the treatment and eradication of hepatitis C, a number of cases of hepatitis B reactivation have been reported in postmarketing treatment outcomes. To date, at least 29 cases h a v e b e e n r e p o r t e d t o t h e U S F o o d a n d D r u g Administration (FDA) Adverse Event Reporting System [41] , including all serologic profiles. Where HBsAg baseline data was available, 76% of reactivation cases (13/17) occurred in patients with positive HBsAg prior to treatment. Few cases have reported baseline HBcAb testing, and it is difficult to assess how prevalent HBV reactivation is amongst patients with isolated HBcAb to date, though emerging reports on cohorts indicate that HBsAg positivity in the absence of suppressive therapy for HBV is a strong risk factor for HBV reactivation (Table 3 ) [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] .
Smaller cohorts such as those described in one Taiwanese and Korean cohort (n = 173) have failed to show evidence of HBV reactivation [45] during HCV treatment with ledipasvirsofosbuvir. In a larger observational cohort in China (n = 327), of which 124 patients were defined as having occult HBV infection, three cases of HBV reactivation have been noted [44] associated with HCV DAA treatment. A large, retrospective evaluation of 62,920 veterans treated for hepatitis C identified nine patients (0.01%) with evidence of HBV reactivation during DAA therapy; one of these nine patients tested positive for isolated HBcAb [42] . Though HBV reactivation would seem in this large retrospective cohort to be an infrequent event, a meta-analysis by Chen and colleagues [43] found more clinical severe reports of hepatitis due to HBV reactivation in patients treated with HCV DAA therapy than interferon-based treatment, as well as an earlier onset of hepatitis in the DAA-treated populations. In general, HBV reactivation occurred 4-8 weeks after initiation of DAA-based therapy, whereas HBV reactivation occurred after cessation of IFN-based HCV therapy [43] . Another retrospective study examined the prevalence of HBV reactivation comparing interferon-era vs interferon-free therapies and found a significant proportion of patients (6/85) experienced HBV viremia during or after DAA treatment, and no cases of reactivation in the interferon based group (0/72) [55] . Together, these findings underscore the importance of screening for chronic or occult hepatitis B infection prior to treatment of HCV with DAAs.
Few data of HBV reactivation exist in HIV-infected populations with respect to interferon-based or DAA-treated cohorts. To date, there has been one case report of HBV reactivation in HIV/HCV co-infection. The patient was anti-HBc and anti-HBs positive who had an acute hepatitis and HBV DNA elevation 4 weeks after completion of SOF/LDV therapy for HCV. She was successfully treated with entecavir with liver enzyme normalization [50] .
Mechanism of HBV Reactivation in HCV Infection HBV and HCV have a unique viral interplay when infection with both viruses exists in one host. In general, HCVexerts an inhibitory effect on HBV, as evidenced by studies finding lower HBV viral loads in co-infection when compared with HBV monoinfected individuals [56] . Presence of HBeAg and levels of HBV DNA have been shown to be significantly lower in patients with HBV/HCV co-infection [57] . Mouse models in vivo have shown that HCV core protein has the capacity to inhibit HBV virus replication [58] . In addition, HBV and HCV may exert varying dominance over the course of each infection [59] . Interferon-based therapy can lead to HBsAg clearance [60, 61] in 30% of dual-infected patients. It is hypothesized that with DAA agents, as there is no inhibitory effect on HBV as with interferon, the ability of HBV to assume viral dominance and replication in the context of HCV clearance may be responsible for cases of HBV reactivation [43] .
Management of Isolated Anti-HBc Pattern Prior to Treatment in HIV/HCV Infection Management of isolated anti-HBc profile in HIV/HCV co-infection remains a subject of discussion, given the risk of HBV reactivation during HCV DAA treatment. In the USA, both the AASLD/IDSA Treatment Guidance and the Veterans' Affairs centers have proposed management algorithms [62, 63] . Our proposed management strategy for addressing isolated anti-HBc serologic profile based on the studies above is shown in Fig. 2 . Using our algorithm, all HIV/HCV co-infected patients should be screened for HBsAg, anti-HBc, and anti-HBs. If the patient is negative for all three markers, it can be concluded that they have had no prior exposure to HBV and are unvaccinated. These patients should then be vaccinated for HBV and do not require further monitoring. HBsAg and anti-HBc negativity with concurrent positive anti-HBs only indicate that the patient has been previously vaccinated with HBV, and therefore requires no further monitoring. If the individual is negative for HBsAg but is positive for both anti-HBc and anti-HBs (demonstrating past HBV infection) or the patient is negative for HBsAg and anti-HBs and is positive for anti-HBc (signifying isolated anti-HBc), we recommend assessment of baseline HBV DNA levels. The presence of HBV DNA requires HBV-active ART initiation. If positive at baseline, HBV DNA should be monitored every 4 weeks during therapy and sustained virologic response 4 and 12 (SVR4 + SVR12) weeks after completion of therapy should also be tested. The optimal treatment duration is unknown. If lifelong therapy is not preferred, HBV active ART should be continued for at 
Summary/Conclusions
The isolated anti-HBc pattern (HBsAg(−)/anti-HBc(+)/antiHBs (−)) occurs in 7-40% of HIV-infected individuals [1, 5, 6, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] and in most cases represents a waning host immune response to HBV infection. The presence of anti-HBc denotes a transcriptionally active reservoir that can result in HBV reactivation. Whether the isolated anti-HBc pattern is associated with greater morbidity in HIV-infected patients is unclear, but large meta-analyses have demonstrated an association with occult HBV infection (one part of the isolated anti-HBc pattern) with chronic liver disease and HCC in non-HIV-infected individuals. The isolated anti-HBc pattern is particularly relevant in HIV/HCV co-infected patients, both with respects to susceptibility to HBV infection and during DAA therapy. HBV reactivation has emerged in the era of DAA treatment of HCV infection, with varying consequences in morbidity ranging from asymptomatic infection to elevations in transaminases and/or resultant liver transplantation. Current guidelines recommended by the American Association for the Study of Liver Diseases (AASLD), and the Veterans' Affairs recommend screening for HBsAg, HBsAb, and anti-HBc prior to consideration of treatment of HCV infection. Adherence to these recommendations and management of occult or isolated anti-HBc, as outlined here, may be essential in the prevention of HBV reactivation and subsequent morbidity that was less appreciated in the interferon era of HCV treatment.
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